Viatris expects 2% revenue and EBITDA growth in 2026 as strategic review targets $650M in cost savings [Seeking Alpha]
Viatris Inc. (VTRS)
Company Research
Source: Seeking Alpha
CEO Scott Smith stated that "2025 was a strong year for Viatris" and highlighted that the company is positioned to "enter a period of long-term sustainable growth beginning in 2026." He emphasized solid results Quick Insights Viatris plans $650M gross cost savings over three years, yielding $400M net after reinvestment, supporting expected 2% revenue and adjusted EBITDA growth for 2026 and laying the groundwork for future margin expansion. Key risks include loss of exclusivity, unfavorable product mix affecting gross margins, pricing pressure in Japan and Asia, execution risks from new product launches, and manufacturing interruptions (e.g., Nashik facility fire); management has incorporated these into 2026 guidance. New launches, especially fast-acting meloxicam and others, are projected to drive $450–$550M in revenue, underpinning the 'base business' growth and supporting the shift to higher, sustainable growth beyond the stabilization expected in 2026. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- What Are Analysts Saying About Viatris Inc (VTRS) Stock? [Yahoo! Finance]Yahoo! Finance
- Assessing Viatris (VTRS) Valuation After Mixed Short And Long Term Share Price Moves [Yahoo! Finance]Yahoo! Finance
- UBS and BofA Lift Price Targets on Viatris (VTRS) [Yahoo! Finance]Yahoo! Finance
- Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research [Yahoo! Finance]Yahoo! Finance
- GoodRx to offer up to 85% discount on Viatris drugs [Seeking Alpha]Seeking Alpha
VTRS
Earnings
- 2/26/26 - Beat
VTRS
Sec Filings
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- VTRS's page on the SEC website